Rapport Therapeutics, Inc. (RAPP) is a Healthcare stock trading at $43.64 (as of 2026-09-11), with a market capitalization of $2.09B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for central nervous system disorders. Its pipeline includes investigational candidates such as RAP-219 and RAP-199, along with nicotinic acetylcholine receptor programs for indications including focal epilepsy and other CNS conditions.
Understand Rapport Therapeutics, Inc.: how it makes money
Rapport Therapeutics develops small-molecule drugs for central nervous system disorders, with lead candidate RAP-219 targeting focal epilepsy, neuropathic pain, and bipolar disorder. As a pre-revenue, single-asset biotech, the entire equity story rides on whether that one molecule clears late-stage trials and wins FDA approval.
Every dollar of equity value is a binary bet on one molecule in one indication; there is no commercial revenue, no portfolio diversification, and no downside protection short of a successful Phase 3 readout and FDA approval.
Business quality (Weak): Pre-revenue, single-asset biotech graded Weak on business quality. All value is optionality on clinical trial readouts, with no recurring revenue, no installed base, and no competitive moat beyond an unproven drug candidate.
Bull case
Novel Mechanism, Multi-Indication Reach: RAP-219 inhibits TARPy8-containing AMPARs, a mechanism distinct from existing anti-epileptic agents, and the same platform extends to peripheral neuropathic pain and bipolar disorder. If efficacy is confirmed in pivotal trials, the company could license out secondary indications or pursue out-licement, creating revenue paths before a full internal commercial buildout.
Phase 2a Efficacy Milestone Achieved: The FOS Phase 2a trial in focal epilepsy has reported its primary and secondary endpoints, clearing the key de-risking gate before a Phase 3 is feasible. This milestone positions the company to seek a regulatory path-forward and to attract a strategic partnership or merger, which is the most common value-realization route for a single-asset CNS biotech.
Bear case
Deep Cash Burn, No Offset: Operating margin stands at -121%, meaning the company spent more than twice its (near-zero) revenue on R&D and operations in the quarter. With no product on the market, every additional trial phase deepens the funding gap, forcing dilutive raises or a partnership to survive to Phase 3 and beyond.
Existential Binary on One Molecule: The entire equity value is tied to RAP-219 clearing a Phase 3 trial and receiving FDA approval. A negative safety signal, a failed pivotal endpoint, or an FDA CRL would eliminate the sole value driver, and there is no secondary product or line of business to absorb that shock. The 10% discontinuation rate from adverse events in earlier trials, while low in absolute terms, is the kind of signal that could halt a program at scale.